×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Why Tempest Therapeutics shares surged 3,973% in a day
Fortune
Shares of Tempest have come off that high in the two latest trading sessions as investor enthusiasm moderated and a broader market selloff in...
7 months ago
Tempest Therapeutics moves TPST-1120 into phase 3 trial By Investing.com
Investing.com
As Tempest Therapeutics, Inc. (NASDAQ: TPST) gears up for a pivotal Phase 3 trial of its cancer treatment candidate TPST-1120, investors are...
1 month ago
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
Advancing TPST-1120 into a pivotal Phase 3 trial in first-line HCC and TPST-1495 into a Phase 2 in FAPReported new preclinical data for...
3 days ago
Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright
MarketBeat
HC Wainwright restated a "buy" rating and set a $47.00 price objective on shares of Tempest Therapeutics in a research report on Friday.
2 days ago
Tempest Therapeutics' stock jumps nearly 4,000% as liver-cancer treatment shows promise
MarketWatch
Referenced Symbols ... Shares of Tempest Therapeutics Inc. TPST soared nearly 4,000% on Wednesday after the company released study results for its...
7 months ago
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid ...
Yahoo Finance
TPST-1120, a first-in-class, oral, selective PPAR⍺ antagonist, demonstrates clinical activity in PD-1 inhibitor refractory and immune...
1 month ago
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
Business Wire
Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Tempest Therapeutics, Inc. (Nasdaq: TPST) concerning the Company and its...
1 month ago
Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch (NASDAQ:TPST)
Seeking Alpha
Tempest Therapeutics got promising results using TPST-1120 + Tecentriq + Avastin for liver cancer and TPST-1495 in endometrial cancer.
4 weeks ago
TPST Stock: 7 Things to Know About Tempest Therapeutics
InvestorPlace
TPST Stock: 7 Things to Know About Tempest Therapeutics ... Today, most of Wall Street is watching Tempest Therapeutics (NASDAQ:TPST). This little...
7 months ago
Tempest Therapeutics Struggles: A Financial Storm Brews Amidst Mounting Losses and Development Hurdles ...
Tipranks
Tempest Therapeutics, Inc. (TPST) has disclosed a new risk, in the Innovation / R&D category. Tempest Therapeutics, Inc., a clinical-stage...
1 month ago